Publication Topic

Bay C, Cyr PL, Jensen IS. Estimating the value of cangrelor from eliminating preloading in coronary artery bypass graft (CABG) patients. ISPOR 16th Annual European Congress, Amsterdam, Netherlands, 2014.

Pinto DS, Nicholson G, Harrington RA, Cyr PL, Bhatt DL. CHAMPION PHOENIX Study economic results: Direct hospitalization costs of patients receiving clopidogrel or cangralor during percutaneous coronary intervention. American Heart Association QCOR conference, Baltimore, MD, 2014.

Olchanski N, McInnis-Myers M, Halseth M, Cyr PL, Bockstedt L, Goss TF, Howland RH. 2013. The economic burden of treatment-resistant depression. Clin Ther 35(4):512-522; doi: 10.1016/j.clinthera.2012.09.001.

Sacks NC. 2013. Avoidable costs in U.S. healthcare: The $200 billion opportunity from using medicines more responsibly. IMS Health, June.

Sacks NC, Burgess JF, Cabral HJ, Pizer SD, McDonnell, ME. 2013. Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries. J Gen Intern Med 28(7):876–885.

Olchanski N, Slawsky KA, Plent S, Kado C, Cyr PL. 2010. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a U.S. hospital. Hosp Prac 38(4):138-146; doi: 10.3810/hp.2010.11.351.

Sacks NC. 2009. Healthcare spending among privately insured individuals under age 65. IMS Health, February.

Sacks NC, Cabral HJ, Kazis LE, Richmond R, Vetter D, Moore TM. 2009. A web-based nutrition program reduces health care costs in employees with cardiac risk factors: Before and after cost analysis. J Med Internet Res 23:11(4):e43; doi: 10.2196/jmir.1263.

Alexander W, Berlin J, Cyr PL, Schofield A, Platt LA. 2004. Realities at the leading edge of research. EMBO Rep 5(4):324-329; doi: 10.1038/sj.embor.7400137.